Suchergebnisse

"Post-traumatic stress disorder (PTSD) is a condition associated with high levels of stress often linked to elevated resting blood pressure (BP). Beta-hydroxybutyrate, a fuel source and signaling molecule, has been shown to improve metabolic and neurological conditions, as well as decrease systolic BP in healthy populations. The purpose of this study was to determine if longterm beta-hydroxybutyrate administration via ketone salt (KS) supplementation alters BP, complete blood count (CBC), or comprehensive metabolic panel (CMP) results in adults diagnosed with PTSD. Sixteen adults (ages 21-65; 12 women/4 men) with PTSD completed this randomized, double-blinded, and placebo-controlled study by taking KS or a placebo supplement for 6 weeks. Blood was collected (for CMP and CBC assessment) and BP measurements were taken before and after the intervention period. None of the variables changed significantly based on the condition (p > .05 for all interaction effects). The reduction in BP measures following the KS supplementation, though non-significant, may be clinically meaningful in PTSD populations and others subject to increased cardiovascular mortality risk. Chronic KS supplementation did not negatively impact BP, CBC, or CMP measures in adults with PTSD. Further investigation of KS as a hypertension treatment approach is warranted in this population."

This study aimed to determine if: 1) C-reactive protein (CRP) level correlated with PTSD symptom severity as measured by PTSD Checklist-5 (PCL-5), and 2) ketone supplement reduced PTSD symptoms. Twenty participants with PTSD were randomly assigned to a ketone supplementation or placebo group and evaluated for 6-weeks for PTSD symptom severity and CRP levels. The Spearman Rank correlation between PCL-5 and CRP was positive, but not statistically significant. Mixed models on the ranks of the data were used to examine the difference in PCL-5 and CRP between ketone and control groups over time. Median PCL-5 at the pre-test was higher than at the post-test in the ketone group but not in the control. The reduction of PCL-5 medians between ketone and control groups at the post-test was not different. The median pre-test CRP was not different from than post-test in the ketone group or control group. This pilot study did not find a correlation between CRP levels and PTSD symptom severity but was limited by a lack of CRP data collection due to the loss of follow-up. PTSD symptom severity was not altered by 6 weeks of chronic ketone salt supplementation compared to the control group but should be examined in a larger sample size for further verification.